18F-FACBC in prostate cancer: A systematic review and meta-analysis

Young AIMN Working Group

Research output: Contribution to journalReview article

Abstract

Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: “FACBC”/“fluciclovine” AND “prostate cancer”/“prostate” AND “PET”/“Positron Emission Tomography”. Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.

Original languageEnglish
Article number11091348
JournalCancers
Volume11
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Meta-Analysis
Prostatic Neoplasms
Prostatic Diseases
Prostate-Specific Antigen
Positron-Emission Tomography
Odds Ratio
Databases
Sensitivity and Specificity
Acids
Positron Emission Tomography Computed Tomography
Therapeutics

Keywords

  • F-FACBC
  • Meta-analysis
  • PET/CT
  • Prostate cancer
  • Recurrence
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

18F-FACBC in prostate cancer : A systematic review and meta-analysis. / Young AIMN Working Group.

In: Cancers, Vol. 11, No. 9, 11091348, 01.01.2019.

Research output: Contribution to journalReview article

Young AIMN Working Group. / 18F-FACBC in prostate cancer : A systematic review and meta-analysis. In: Cancers. 2019 ; Vol. 11, No. 9.
@article{fa1093dc947141cb95a81510dd518bb9,
title = "18F-FACBC in prostate cancer: A systematic review and meta-analysis",
abstract = "Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: “FACBC”/“fluciclovine” AND “prostate cancer”/“prostate” AND “PET”/“Positron Emission Tomography”. Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3{\%} and 75.9{\%}, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30{\%}. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4{\%} vs. 76.5{\%}, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89{\%} vs. 45{\%}, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.",
keywords = "F-FACBC, Meta-analysis, PET/CT, Prostate cancer, Recurrence, Review",
author = "{Young AIMN Working Group} and Riccardo Laudicella and Domenico Albano and Pierpaolo Alongi and Giovanni Argiroffi and Matteo Bauckneht and Sergio Baldari and Francesco Bertagna and Michele Boero and {De Vincentis}, Giuseppe and {Del Sole}, Angelo and Giuseppe Rubini and Lorenzo Fantechi and Viviana Frantellizzi and Gloria Ganduscio and Priscilla Guglielmo and Nappi, {Anna Giulia} and Laura Evangelista",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/cancers11091348",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "9",

}

TY - JOUR

T1 - 18F-FACBC in prostate cancer

T2 - A systematic review and meta-analysis

AU - Young AIMN Working Group

AU - Laudicella, Riccardo

AU - Albano, Domenico

AU - Alongi, Pierpaolo

AU - Argiroffi, Giovanni

AU - Bauckneht, Matteo

AU - Baldari, Sergio

AU - Bertagna, Francesco

AU - Boero, Michele

AU - De Vincentis, Giuseppe

AU - Del Sole, Angelo

AU - Rubini, Giuseppe

AU - Fantechi, Lorenzo

AU - Frantellizzi, Viviana

AU - Ganduscio, Gloria

AU - Guglielmo, Priscilla

AU - Nappi, Anna Giulia

AU - Evangelista, Laura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: “FACBC”/“fluciclovine” AND “prostate cancer”/“prostate” AND “PET”/“Positron Emission Tomography”. Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.

AB - Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: “FACBC”/“fluciclovine” AND “prostate cancer”/“prostate” AND “PET”/“Positron Emission Tomography”. Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.

KW - F-FACBC

KW - Meta-analysis

KW - PET/CT

KW - Prostate cancer

KW - Recurrence

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85073165083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073165083&partnerID=8YFLogxK

U2 - 10.3390/cancers11091348

DO - 10.3390/cancers11091348

M3 - Review article

AN - SCOPUS:85073165083

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 9

M1 - 11091348

ER -